ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年06月09日 10時00分
Source:
Eisai
エーザイ、2023年3月期業績予想（IFRS）の修正に関するお知らせ
東京, 2022年06月09日 - (JCN Newswire) - 直近の業績の動向等を踏まえ、2022年5月13日に公表した2023年3月期（2022年4月1日から2023年3月31日）の業績予想を下記のとおり修正しますのでお知らせします。
1. 2023年3月期の連結業績予想数値の修正（2022年4月1日から2023年3月31日）
※ご参照
https://www.eisai.co.jp/news/2022/news202246.html
2. 修正の理由
当期において、当社が保有する一部株式について株式譲渡益10億円が発生する見込みです。加えて、当社の資本政策の一環としてグローバルな資金配分の最適化を企図し、米国の連結子会社から資金を回収するために当社が米国子会社から払込資本の払戻しを受けた結果、税務上の譲渡損失等が当社にて発生し、法人所得税が従来の想定を下回ることを見込んでいます。これらにより、当期利益を前回予想から115億円増の580億円、親会社の所有者に帰属する当期利益を前回予想から115億円増の570億円に修正します。ROE（親会社所有者帰属持分当期利益率）は7.5％を見込みます。
売上収益、営業利益については、前回予想から変更ありません。
なお、1株当たり160円の年間配当金（第2四半期末80円、期末80円）の予定に変更はありません。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202246.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
NEC improves the energy efficiency and floor space density of 5G Mobile Core systems
Mar 06, 2025 13:20 JST
Unmanned Aerial Vehicles Being Developed by MHI Used in Demonstration of Automated Transport and Unloading of Heavy Cargo in Disaster Areas
Mar 05, 2025 16:11 JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 05, 2025 09:09 JST
MHI-MS Completes Domestic Development of Vehicle Transport Robot
Mar 04, 2025 19:39 JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 04, 2025 17:22 JST
Prideone Entertainment announces concept for post-war film to mark 80th anniversary of the end of World War II
Mar 04, 2025 16:00 JST
NTT and DOCOMO Successfully Demonstrates On-Demand Unified Control of Computing Services Through Network and Service Integration
Mar 03, 2025 20:25 JST
Space Compass and NTT DOCOMO Successfully Demonstrate Data Connectivity to 4G Devices via HAPS at 20 km Above Kenya
Mar 03, 2025 20:14 JST
TOPPAN and DOCOMO Agree to Innovate Next-Generation 6G Services Using FEEL TECH Communication Technology
Mar 03, 2025 18:32 JST
Rakuten Mobile Partners with Fujitsu to Accelerate 5G Network Expansion
Mar 03, 2025 18:23 JST
Fujitsu unveils 1FINITY 800G ZR/ZR+ coherent pluggable transceivers
Mar 03, 2025 17:58 JST
NEC develops and commercializes 5G-compatible virtualized base stations (vRAN)
Mar 03, 2025 17:42 JST
MHI-MS Delivers Merging Support Information System for Autonomous Truck Trial Project by MLIT
Mar 03, 2025 16:09 JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 03, 2025 15:41 JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Mar 03, 2025 13:53 JST
Fujitsu's Oyama plant achieves top CSR score for sustainability in global telecom audit
Feb 28, 2025 16:57 JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 28, 2025 12:31 JST
NEC introduces solution to enhance the security of Open vRAN
Feb 28, 2025 11:30 JST
Mazda Production and Sales Results for January 2025
Feb 27, 2025 18:20 JST
Toyota Submits Second Progress Report on Measures to Prevent Recurrence
Feb 27, 2025 18:00 JST
More Latest Release >>
Related Release
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
2/14/2025 12:09:00 PM JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
2/3/2025 5:23:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
1/22/2025 5:18:00 PM JST
More Press release >>